Enveric Biosciences, Inc. (ENVB) Fair Value 2026

ENVB · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 1 models active

Value Trap Risk

DANGER (68/100)

Quick Summary — As of 2026-10-07, Enveric Biosciences, Inc. (ENVB) trades at $1.47. QOC: 4.3/10. Value Trap Risk: 68/100 (DANGER). 1/13 models active.

Key Facts

Ticker
ENVB
Price
$1.47
Quality Score
4.3/10
Value Trap Risk
68/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 68 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give ENVB?

1 Intrinsic Value Models vs. Current Price ($1.47)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $1.35 -7.9%

All Models Active

All 1 models are displayed above.

What Is Enveric Biosciences, Inc. (ENVB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Enveric Biosciences, Inc.'s intrinsic value is estimated at $1.35, suggesting the stock is overvalued at its current price of $1.47. With 1 out of 1 models flagging downside (-7.9% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About ENVB?

1 of 13 models are currently active for ENVB. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does ENVB Rank in Biotechnology?

Among 622 Biotechnology stocks, ENVB ranks #492 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Enveric Biosciences, Inc. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is ENVB a Value Trap?

CirclFi's Value Trap algorithm assigns ENVB a score of 68/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Enveric Biosciences, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Enveric Biosciences, Inc. is rated at 4.3/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses. Notably, value trap risk is elevated.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ENVB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ENVB's 1 active models, average confidence is 57%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Enveric Biosciences, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BBLGBone Biologics CorporationQOC 4.3DCOYDecoy Therapeutics Inc.QOC 4.3PASGPassage Bio, Inc.QOC 4.3GUTSFractyl Health, Inc.QOC 4.2PALIPalisade Bio, Inc.QOC 4.3TENXTenax Therapeutics, Inc.QOC 4.2VXRTVaxart, Inc.QOC 8.1OABIOmniAb, Inc.QOC 5.7OSRHOSR Health, Inc.QOC 4.9EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BBLG · DCOY · PASG · GUTS · PALI · TENX · VXRT · OABI · OSRH · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ENVB?

7 companies across all industries closest to ENVB’s Quality of Company score of 4.3/10.

FEAV5E Advanced Materials, Inc.QOC 4.3KRFGKing Resources, IncQOC 4.3EDBLEdible Garden AG IncorporatedQOC 4.3LTUMLithium CorporationQOC 4.3HNOIHNO International, Inc.QOC 4.3KXINKaixin HoldingsQOC 4.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FEAV · KRFG · EDBL · LTUM · HNOI · KXIN · NVDA

Where Does ENVB Sit in CirclFi's Biotechnology Rankings?

ENVB is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Enveric Biosciences, Inc.’s Valuation?

What is Enveric Biosciences, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Enveric Biosciences, Inc. (ENVB). The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ENVB overvalued or undervalued right now?

At $1.47, 0 of 1 active models suggest ENVB may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Enveric Biosciences, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.3 mean for ENVB?

Enveric Biosciences, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ENVB?

CirclFi analyzes ENVB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is ENVB a value trap in 2026?

Enveric Biosciences, Inc.'s Value Trap score is 68/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Enveric Biosciences, Inc. (ENVB) a Quality of Company score of 4.3/10 across 32 fundamental signals as of 2026-10-07.” Source: circlfi.com/stock/ENVB/ · Methodology
Primary sources for this ENVB valuation
  • Financial statements: Enveric Biosciences, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000890821) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ENVB as of ; valuations recomputed .